What is AceCann?
AceCann is dedicated to producing consistent, high-quality medical cannabis products designed to provide patients with access to life-changing innovation and improved health outcomes. Operating under stringent pharmaceutical standards, AceCann has carved out a unique position within the rapidly expanding medical cannabis market. Founded in 2019 and headquartered in Lisbon, Portugal, the company emphasizes pharmaceutical-grade production to differentiate its offerings.
How much funding has AceCann raised?
AceCann has raised a total of $15M across 1 funding round:
Angel/Seed
$15M
Angel/Seed (2021): $15M with participation from Frank Cid, Chris Mayle, Lince Capital, Marc Gare, Casa Verde Capital, and Sebastian de la Rosa
Key Investors in AceCann
Lince Capital
Lince Capital is a financial solutions firm specializing in commercial promotion and financing, based in So Caetano do Sul.
Casa Verde Capital
Casa Verde Capital is a leading venture capital firm exclusively focused on the cannabis industry, investing in scalable businesses addressing long-term market needs.
What's next for AceCann?
The substantial enterprise-level funding and recent strategic investment signal AceCann's transition into a scaling phase. This capital infusion is poised to accelerate product development, enhance manufacturing capabilities, and broaden market reach. AceCann's focus on pharmaceutical standards suggests a strategy aimed at capturing a significant share of the regulated medical cannabis market, potentially through strategic partnerships and further research initiatives. The company's trajectory indicates a strong commitment to innovation and patient access.
See full AceCann company page
